{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:39:08Z","timestamp":1758591548627,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["FT210100656"],"award-info":[{"award-number":["FT210100656"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1173505"],"award-info":[{"award-number":["APP1173505"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Public Health"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.puhe.2023.08.019","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T01:08:56Z","timestamp":1695344936000},"page":"90-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-0075","authenticated-orcid":false,"given":"A.","family":"Roxburgh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"S.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-5753","authenticated-orcid":false,"given":"S.","family":"Cogger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-1412","authenticated-orcid":false,"given":"C.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Latimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jauncey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6183","authenticated-orcid":false,"given":"N.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"Harm reduction responses to COVID-19 in Europe: regularly updated infopage","author":"Sarosi","key":"10.1016\/j.puhe.2023.08.019_bib1"},{"key":"10.1016\/j.puhe.2023.08.019_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.puhe.2021.01.004","article-title":"Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services","volume":"192","author":"Croxford","year":"2021","journal-title":"Publ Health"},{"key":"10.1016\/j.puhe.2023.08.019_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102851","article-title":"The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England","volume":"83","author":"Whitfield","year":"2020","journal-title":"Int J Drug Pol"},{"issue":"6","key":"10.1016\/j.puhe.2023.08.019_bib4","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1097\/ADM.0000000000000753","article-title":"Access to healthcare and harm reduction services during the COVID-19 pandemic for people who use drugs","volume":"14","author":"Stowe","year":"2020","journal-title":"J\u00a0Addiction Med"},{"key":"10.1016\/j.puhe.2023.08.019_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.639393","article-title":"Reorganization of substance use treatment and harm reduction services during\u00a0the COVID-19 pandemic: a global survey","volume":"12","author":"Radfar","year":"2021","journal-title":"Front Psychiatr"},{"issue":"1","key":"10.1016\/j.puhe.2023.08.019_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12954-020-00370-7","article-title":"Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic","volume":"17","author":"Dunlop","year":"2020","journal-title":"Harm Reduct J"},{"issue":"1","key":"10.1016\/j.puhe.2023.08.019_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12954-021-00471-x","article-title":"Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia","volume":"18","author":"Roxburgh","year":"2021","journal-title":"Harm Reduct J"},{"issue":"12","key":"10.1016\/j.puhe.2023.08.019_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244809","article-title":"Impact of COVID-19 pandemic on mental health: an international study","volume":"15","author":"Gloster","year":"2020","journal-title":"PLoS One"},{"issue":"6489","key":"10.1016\/j.puhe.2023.08.019_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.aba9757","article-title":"The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak","volume":"368","author":"Chinazzi","year":"2020","journal-title":"Science"},{"year":"2020","series-title":"A\u00a0timeline of alcohol-relevant restrictions during the COVID-19 pandemic","author":"Miller","key":"10.1016\/j.puhe.2023.08.019_bib10"},{"key":"10.1016\/j.puhe.2023.08.019_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103391","article-title":"Living under Coronavirus and Injecting Drugs in Bristol (LUCID-B): a qualitative study of experiences of COVID-19 among people who inject drugs","volume":"98","author":"Kesten","year":"2021","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.puhe.2023.08.019_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103561","article-title":"Drug markets and COVID-19: a spatiotemporal study of drug offence detection rates in Brisbane, Australia","volume":"101","author":"Payne","year":"2022","journal-title":"Int J Drug Pol"},{"issue":"6","key":"10.1016\/j.puhe.2023.08.019_bib13","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/dar.13456","article-title":"Health service utilisation and access for people who inject drugs during COVID-19","volume":"41","author":"Efunnuga","year":"2022","journal-title":"Drug Alcohol Rev"},{"year":"2021","series-title":"Impact of Melbourne's second wave of COVID-19 and associated restrictions among people who inject drugs: preliminary findings from the Illicit Drug Reporting System","author":"Eddy","key":"10.1016\/j.puhe.2023.08.019_bib14"},{"issue":"4","key":"10.1016\/j.puhe.2023.08.019_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/dar.13079","article-title":"Illicit drug use and harms in Australia in the context of COVID-19 and associated restrictions: anticipated consequences and initial responses","volume":"39","author":"Dietze","year":"2020","journal-title":"Drug Alcohol Rev"},{"year":"2020","series-title":"By the double: COVID-19, opioids, and the threat of a syndemic","author":"Nielsen","key":"10.1016\/j.puhe.2023.08.019_bib16"},{"year":"2020","series-title":"Review of the medically supervised injecting room","key":"10.1016\/j.puhe.2023.08.019_bib17"},{"key":"10.1016\/j.puhe.2023.08.019_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drugalcdep.2007.07.020","article-title":"Characteristics of drug-related hospital separations in Australia","volume":"92","author":"Roxburgh","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.puhe.2023.08.019_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/09595230412331289446","article-title":"Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia","volume":"23","author":"Roxburgh","year":"2004","journal-title":"Drug Alcohol Rev"},{"year":"2020","series-title":"COVID-19 and the drug supply chain: from production and trafficking to use","key":"10.1016\/j.puhe.2023.08.019_bib20"},{"key":"10.1016\/j.puhe.2023.08.019_bib21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drugalcdep.2017.02.027","article-title":"Frequency and severity of non-fatal opioid overdoses among clients attending the Sydney Medically Supervised Injecting Centre","volume":"176","author":"Roxburgh","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.puhe.2023.08.019_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107909","article-title":"Substances injected at the Sydney supervised injecting facility: a chemical analysis of used injecting equipment and comparison with self-reported drug type","volume":"209","author":"Lefrancois","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.puhe.2023.08.019_bib23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1536867X1501500208","article-title":"Conducting interrupted time-series analysis for single-and multiple-group comparisons","volume":"15","author":"Linden","year":"2015","journal-title":"STATA J"},{"volume":"vol. 17","year":"2021","key":"10.1016\/j.puhe.2023.08.019_bib24"},{"year":"2022","series-title":"Victorian drug trends 2022: key findings from the illicit drug reporting system (IDRS) interviews","author":"Eddy","key":"10.1016\/j.puhe.2023.08.019_bib25"},{"key":"10.1016\/j.puhe.2023.08.019_bib26","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.toxac.2022.06.020","article-title":"Toxicity of heroin laced with synthetic opioid \u03b2-U10 and etizolam","volume":"34","author":"Di Rago","year":"2022","journal-title":"Toxicologie Analytique et Clinique"},{"year":"2022","series-title":"New South wales drug trends 2022: key findings from the illicit drug reporting system (IDRS) interviews","author":"Jones","key":"10.1016\/j.puhe.2023.08.019_bib27"},{"issue":"8","key":"10.1016\/j.puhe.2023.08.019_bib28","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/add.15832","article-title":"Infrequent detection of unintentional fentanyl use via urinalysis among people who regularly inject opioids in Sydney and Melbourne, Australia","volume":"117","author":"Lam","year":"2022","journal-title":"Addiction"},{"year":"2022","series-title":"Victorian overdose deaths: quarterly update to June 2022","key":"10.1016\/j.puhe.2023.08.019_bib29"},{"year":"2022","series-title":"Trends in drug-related hospitalisations in New South Wwales, 1999-2021","author":"Chrzanowska","key":"10.1016\/j.puhe.2023.08.019_bib30"},{"year":"2021","series-title":"Australian drug trends 2021: key findings from the national illicit drug reporting system (IDRS) interviews","author":"Sutherland","key":"10.1016\/j.puhe.2023.08.019_bib31"},{"issue":"8","key":"10.1016\/j.puhe.2023.08.019_bib32","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/add.16189","article-title":"The impacts of COVID-19 measures on drug markets and drug use among a cohort of people who use methamphetamine in Victoria, Australia","volume":"118","author":"Rathnayake","year":"2023","journal-title":"Addiction"}],"container-title":["Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003335062300313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003335062300313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:41:56Z","timestamp":1758501716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003335062300313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":32,"alternative-id":["S003335062300313X"],"URL":"https:\/\/doi.org\/10.1016\/j.puhe.2023.08.019","relation":{},"ISSN":["0033-3506"],"issn-type":[{"type":"print","value":"0033-3506"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia","name":"articletitle","label":"Article Title"},{"value":"Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.puhe.2023.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}